Tiziana Life Sciences (TLSA) announced that its Phase 2 clinical trial evaluating intranasal foralumab in patients with amyotrophic lateral sclerosis, ALS, has been accepted for inclusion in the ALS ...

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that eventually robs them of the ability to move, speak, eat or breathe. Now, ...

President Donald Trump plugged the Kennedy Center Honors ceremony on social media ahead of its airing Tuesday night, asking American viewers to tell him what they think about his hosting of the event ...